SGLT2 inhibitors: not every drug has the same effect

Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F1039-F1040. doi: 10.1152/ajprenal.00126.2024. Epub 2024 May 2.

Author

Alexander Staruschenko^{1

2

3}

Affiliations

¹ Department of Molecular Pharmacology and Physiology, University of South Florida, Tampa, Florida, United States.
² Hypertension and Kidney Research Center, University of South FloridaTampa, Florida, United States.
³ James A. Haley Veterans Hospital, Tampa, Florida, United States.

PMID: 38695073
DOI: 10.1152/ajprenal.00126.2024

No abstract available

Keywords: NHE3; SGLT2 inhibitors; canagliflozin; empagliflozin; proximal tubule.

Publication types

Editorial
Comment

MeSH terms

Animals
Diabetes Mellitus, Type 2 / drug therapy
Diabetic Nephropathies / drug therapy
Humans
Hypoglycemic Agents / pharmacology
Hypoglycemic Agents / therapeutic use
Kidney / drug effects
Kidney / metabolism
Sodium-Glucose Transporter 2 / metabolism
Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2

Grants and funding